



Press Release
July 4, 2012
Gothenburg, Sweden

EmbryoGlue® gives hope to infertile couples

In a study presented at the on-going ESHRE conference in Istanbul, Vitrolife's patent protected medium EmbryoGlue® has once again been proven to increase both implantation and pregnancy rates, regardless of hormone stimulation of the endometrium or not.

Dr. Nakagawa from Japan, who performed the study, investigated whether the preparation method of the endometrium, the lining of the uterus, before transfer had an effect on pregnancy rate or not. The prospective randomized study included 203 patients under the age of 40, all with four or more previous implantation failures. 101 of the women had embryo transfer in a natural ovulation cycle, and 102 women were prepared by hormone replacement cycle. Patients in each group were allocated to transfer with either EmbryoGlue® or a transfer medium with no hyaluronan.

The study showed that the pregnancy rate increased significantly for the group receiving transfer in EmbryoGlue®. In the group with natural cycles it increased from 10% till 31.4% and in the group receiving transfer in a hormone stimulated cycle from 15.7% to 41.2%

"I am very happy to present these data, showing that women with many previous implantation failures have a chance of becoming parents," says Dr. Nakagawa.

EmbryoGlue® is a medium patent protected by Vitrolife, enriched with hyaluronan, a natural substance abundant in all tissues in the body. It has a unique combination of a high concentration of hyaluronan and recombinant albumin. EmbryoGlue® is used when transferring embryos into the woman as the final step of an IVF treatment.

The use of EmbryoGlue® for embryo transfer has been analysed in numerous studies, showing an increased treatment success independent of patient age, day of transfer and now also preparation of the endometrium.

July 4, 2012
Gothenburg, Sweden
VITROLIFE AB (publ)
Thomas Axelsson
CEO

For further information, please contact:

Thomas Axelsson, CEO, +46 31 721 80 01
Mikael Engblom, CFO, phone +46 31 721 80 14

[Vitrolife](#) is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The [Fertility](#) product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The [Transplantation](#) product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

[Vitrolife](#) today has approximately 220 employees and the company's products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The [Vitrolife share](#) is listed on [NASDAQ OMX Stockholm](#), Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 4, 2012 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.